La vancomycine est l'un des antibiotiques les plus prescrits, principalement utilisé pour les infections suspectées et confirmées à Staphylococcus aureus résistant à la méthicilline (SARM). Les infections par des souches de SARM font peser une charge importante sur le système de santé, à laquelle s'ajoute l'incertitude qui demeure quant à la posologie optimale de la vancomycine. Les récentes lignes directrices révisées sur le suivi thérapeutique de la vancomycine, publiées en 2020, avalisent principalement l'estimation directe de l'aire sous la courbe de concentration en fonction du temps (AUC) par l'utilisation d'équations bayésiennes ou pharmacocinétiques (PK) de premier ordre pour le suivi thérapeutique. Pour mieux informer la posologie de la vancomycine, nous avons d'abord mis à jour une revue précédente des analyses pharmacocinétiques de population (PopPK) de la vancomycine publiées chez les adultes et les enfants. Pour ce faire, nous avons déterminé les caractéristiques des modèles pharmacocinétiques rapportés et identifié les diverses sources potentielles de variabilité observées dans différentes sous-populations particulières. Motivés par la controverse existante autour des nouvelles directives de surveillance thérapeutique de la vancomycine et par l'absence d'une étude approfondie des méthodes recommandées, nous avons recueilli des données hospitalières et construit un cadre de modélisation qui nous a permis d'évaluer les recommandations des directives sur les méthodes de surveillance, tout en considérant une variété de scénarios et d'hypothèses cliniques réalistes. Notre analyse a confirmé que la surveillance bayésienne est la méthode la plus rapide et la plus fiable, à condition qu'elle soit correctement mise en œuvre, la plus importante condition pour cela étant l'utilisation de modèles bayésiens a priori appropriés. De plus, nous avons montré que le suivi bayésien ne nécessite pas nécessairement des niveaux de concentration de types creux ou pic et peut en fait être réalisé en utilisant un niveau aléatoire. Aussi, nous avons démontré que l'utilisation correcte des équations pharmacocinétiques de premier ordre exigerait au moins deux mesures de concentration à l'état d'équilibre. L’utilisation de la méthode creux-seulement de la vancomycine à l'état d'équilibre peut être tout aussi efficace dans certaines situations que nous avons explorées ici. En considérant la larges étendue et la grande variabilité des populations traitées à la vancomycine en termes d'âge, de gravité de l'infection et de scénarios cliniques, cette thèse adopte un regard objectif pour évaluer quantitativement le gain potentiel de chaque méthode de surveillance de la vancomycine, en explorant leur adéquation en termes d'effort nécessaire, de disponibilité des ressources et de gain potentiel. Compte tenu des lignes directrices sur la vancomycine récemment publiées et de la controverse qui persiste, nous pensons que cette thèse a permis de démêler la variété et la complexité de l'utilisation de la vancomycine et a apporté un éclairage supplémentaire plus objectifvement informé vers un suivi thérapeutique optimal de la vancomycine. / Vancomycin is among the most prescribed antibiotics, mainly used for suspected and confirmed methicillin-resistant Staphylococcus aureus (MRSA) infections. Infections by MRSA strains carry a substantial burden on the health care system, supplemented by the uncertainty that remains regarding vancomycin optimal dosing. The recent revised vancomycin therapeutic monitoring guidelines published in 2020, endorsed primarily the direct estimation of area under the concentration-time curve (AUC) through the use of Bayesian or first-order pharmacokinetic (PK) equations monitoring. To better inform vancomycin dosing, we first updated a previous review of published vancomycin population pharmacokinetic (PopPK) analysis in both adults and children. This was accomplished by determining the characteristics of the reported pharmacokinetic models and identifying the potential various sources of variability observed in different special subpopulations. Motivated by the existing controversy around the new vancomycin therapeutic monitoring guidelines and the lack of a thorough investigation of the recommended methods, we collected hospital data and built a modeling framework that allowed us to assess the guideline recommendations of monitoring methods while considering a variety of realistic clinical scenarios and assumptions. Our analysis affirmed that Bayesian monitoring is the fastest and most reliable method, conditional on its proper implementation, the most important being the use of proper Bayesian priors. Moreover, we showed that Bayesian monitoring does not necessarily require trough or peak concentration levels and can in fact be performed using a random level. Proper use of first-order PK equations required at least two steady-state concentration measurements. Alternatively, simpler trough-only vancomycin monitoring near steady-state can be as effective in certain cases that we explored here. By considering the wide ranges and the high variability in populations treated with vancomycin in terms of age, the severity of infection, and clinical scenarios, this thesis takes an objective look to quantitatively assess the potential gain of each vancomycin drug monitoring method, by investigating their suitability in terms of the effort needed, the availability of resources and the resulting gain. Considering the recently released vancomycin guidelines and the ensuing controversies between well-established clinical teams, we believe that this dissertation helped untangle the variety and complexity of vancomycin use and brought additional insights towards a more objective and optimal vancomycin therapeutic monitoring.

This master’s thesis determines trail suitability in the context of environmental area sensitivity, closely focusing on a proposed Bästeträsk National Park, Gotland, Sweden. The current relative low usage of the area is expected to significantly increase its tourism flow once the proposed national park is established, as the demand for nature-based tourism and recreation is growing. However, due to its pristine landscapes, myriad endemic and red-listed species, and rare geomorphological phenomena, there is a need to closely review the destination’s environmental sensitivity and potential recreational adverse impacts on the area’s ecosystem services. Consequently, the research reviews Volunteered Geographic Data within the studied area and employs Geographic Information Systems-based Multi-Criteria Decision Analysis to determine environmental trail suitability. The research identified that more than half of the studied area exhibits substantial environmental sensitivity. Additionally, it highlights that multiple used and established trails intersect considerably sensitive areas, which must be considered for future tourism planning to attain sustainable destination development. Moreover, the study furthers on the requisite to recognise nature-based activities beyond the means of low impact due to their increasing popularity and anthropogenic impacts.

The Trail Member of the upper Cretaceous Ericson Sandstone, part of the Mesaverde Group, is exposed along hundreds of square kilometers through Wyoming along the flanks of several Laramide structural uplifts. This presents a unique opportunity to study the detailed architecture based on bed-scale heterogeneity and better assess the reservoir potential of these strata in outcrop exposure on a regional-scale, and to then relate these observations to producing fields nearby. The fluvial-dominated Trail Member formed as sediments traveled from the active Sevier thrust belt to the Cretaceous Interior Seaway, forming a basinward progradational clastic wedge along a relatively high gradient. The high energy, tectonically active setting led to preservation of sand-rich, often compositionally immature fluvial strata. Though there is an abundance of sand-rich strata in the Trail Member, production from this interval has been unpredictable in current and past fields such as the Trail Unit of southwestern Wyoming.Twelve detailed stratigraphic columns were described at three sites along the eastern flank of the Rock Springs Uplift to show facies heterogeneity beyond what is often available through wells, 69 hand samples were collected for determination of porosity and permeability, and photogrammetric characterization was performed at the three sites. Average porosity decreases along strike from north to south along with net-to-gross. The vertical changes in fluvial architecture within the Trail Member reflect changes in available accommodation. While thickness of the Trail Member is highly variable, ranging between 79 to 108 meters across the study area, there is an overall trend of thickening to the south. Although the character of the Trail strata changes appreciably along strike direction, this interval is consistently rich in sand, and grain size does not change drastically along the length of observed outcrops. This study demonstrated that spatial variability in the thickness, local accommodation, porosity, and net-to-gross of the Trail Member, as well as temporal variability in the amount and character of reservoir sands and channel stacking patterns play an important role in the unpredictability of this reservoir. This study will enable reservoir modeling and aid in future exploration projects within the Trail Member and other comparable systems with similar fluvial architecture and internal heterogeneity.

No description available.

No description available.

Multiple Sklerose (MS) ist eine heterogene Krankheit des Zentralnervensystems, deren pathologische Mechanismen noch nicht vollständig aufgeklärt sind. Die gegenwärtige Hypothese ist, daß pro-inflammatorische T-Zellen entscheidend an der Pathogenese der MS beteiligt sind. Man geht davon aus, daß eine Fehlregulation der T-Zell-Kontrolle, möglicherweise bedingt durch ein Ungleichgewicht an Apoptose-regulierenden Molekülen, dabei eine Rolle spielt. Tatsächlich zielen therapeutische Strategien darauf ab, T-Zell-Aktivierung, Proliferation und Produktion von Zytokinen zu verringern, oder T-Zell-Eliminierung zu fördern. Diese Arbeit sollte zum einen die Bedeutung regulatorischer Faktoren klären, die für das überleben der T-Zellen von MS-Patienten verantwortlich sind. Zum anderen sollten die antiproliferative oder Apoptose-fördende Wirkung potentiell therapeutisch wirksamer Moleküle untersucht werden. Eine eingeschränkte Regulation der autoreaktiven T-Zellen durch Apoptose in der Peripherie und im ZNS trägt möglicherweise zur Pathophysiologie der MS bei. Als Schlüsselfaktoren der Regulation von Apoptose wurden Mitglieder der Bcl-2-Familie in MS-Patienten und Probanden untersucht. Diese Faktoren wurden in Relation zu der Suszeptibilität der T-Zellen gegenüber aktivierungsinduziertem Zelltod (sog. Activation-induced cell death oder AICD) überprüft. Um die in-vivo-Elimination der Antigen-reaktiven T-Zellen nachzuahmen, wurde ein in-vitro-Modell des AICD mit repetitiver T-Zell-Stimulation verwendet. Tatsächlich zeigten polyklonale T-Zellen von MS-Patienten eine verringerte Suszeptibilität für AICD, nachgewiesen sowohl durch verminderte Caspaseaktivtät (p=0.013) als auch durch DNA-Fragmentierung (p=0.0071). Weiter wurden höhere Spiegel des Proteins Bcl-XL in den Immunzellen von MS-Patienten mit Immunoblotting gemessen (p=0.014). Eine inverse Korrelation zwischen der Expression an Bcl-XL und der Empfindlichkeit der T-Zellen gegenüber AICD steht in Übereinstimmung mit vorhergehenden Daten bezüglich der Bedeutung dieses Proteins für die Apoptose-Resistenz von T-Zellen. Es wurde bereits gezeigt, daß dieses Molekül die Ausprägung der experimentell-autoimmun Enzephalomyelitis, des Tiermodells der MS, verstärkt. Zusammen mit den erhöhten Bcl-XL-Werten bei MS-Patienten, ergeben sich nun Perspektiven für einen therapeutischen Ansatz. Abgesehen von dem Konzept die apoptotische Eliminierung von T-Zellen zu unterstützen, streben gegenwärtige therapeutische Strategien an, die Aktivierung und weitere Proliferation der schädlichen T-Zellen zu hemmen. Basierend auf klinischer Erfahrung mit eher unselektiven Therapien, ist es ein therapeutisches Ziel, neue immunomodulatorische Substanzen mit besserer Selektivität zu finden, um das Nutzen/Risiko-Verhältnis zu maximieren. Aus diesem Grund wurden zwei unterschiedliche Substanzen untersucht die beide den Zellzyklus beeinflussen. Als erster Kandidat wurde der kürzlich entdeckte Todesligand TRAIL (engl.: TNF-related apoptosis inducing ligand) aus der TNF/NGF-Familie untersucht, da diesem bereits T-Zell-regulatorische Funktionen zugeschrieben worden waren, humane Antigen-spezifische T-Zellen jedoch resistent gegenüber TRAIL-induzierter Apoptose sind. Der zweite Kandidat mit potenziell therapeutischer Wirkung bei MS ist Atorvastatin, ein HMG-CoA-Reduktase-Hemmer, der bereits als Lipidsenker bei Patienten eingesetzt wird. Um die Hypothese zu überprüfen, daß diese Substanzen T-Zell-Rezeptor-Signale beeinflussen können, wurden humane Antigen-spezifische T-Zell-Linien von MS-Patienten und gesunden Probanden eingesetzt. Diese wurden hinsichtlich T-Helfer-Phänotyp und Peptid-Spezifität charakterisiert. Eine Behandlung mit TRAIL führte zur Hemmung der Proliferation in unterschiedlichem Ausmaß (6.2% - 63.8%). Atorvastatin hemmte in Abhängigkeit von der Dosis ebenso die Proliferation Antigen-spezifischer T-Zellen. Beide Substanzen wirkten antiproliferativ unabhängig von der Antigenpräsentation, aufgrund ihrer Fähigkeit, die Proliferation in Abwesenheit von professionellen Antigen-präsentierenden Zellen zu vermindern. Diese Eigenschaft weißt auf einen direkten Einfluß auf die T-Zell-Funktion hin. Die TRAIL-induzierte Hypoproliferation war assoziiert mit einer Herunterregulation der Zyklin-abhängigen Kinase CDK4 (engl.: cyclin dependent kinase 4), einem Schlüsselenzym für die nach T-Zell-Rezeptor-Stimulation einsetzende Transition von der G1- zur S-Phase des Zellzyklus. Inkubation mit Atorvastatin induzierte ebenso eine Verminderung von CDK4, begleitet von einer Erhöhung von p27Kip1. Die Atorvastatin-vermittelte Proliferations- und Zellzyklus-Blockade konnte durch Mevalonat rückgängig gemacht werden. Mevalonat ist ein Zwischenprodukt des HMG-CoA-Reduktaseweges. Atorvastatin scheint demnach einen direkten Einfluß auf diese Enzymkaskade zu haben, der wichtig für die Isoprenylierung von GTPase-Proteinen der Rho-Familie ist. T-Zell-Rezeptor-Stimulation führt zur Freisetzung von Kalzium aus intrazellulären Speichern und nachfolgend zur Öffnung transmembranöser Kalzium-Kanäle (sog. calcium release-activated calcium oder CRAC-Kanäle), die eine für die T-Zellaktivierung notwendige und anhaltende Erhöhung der intrazellulären Kalzium-Konzentration hervorruft. Nach Behandlung mit TRAIL wurde eine konzentrationsabhängige Inhibition des Einstroms extrazellulärer Kalzium-Ionen durch die CRAC-Kanäle beobachtet. Dies wurde mit löslichem TRAIL-Rezeptor-Fusionsprotein, einem TRAIL-Antagonisten, rückgängig gemacht. Die Blockade von Kalzium-abhängigen Aktivierungssignalen stellt damit möglicherweise einen primären immunregulatorischen Mechanismus für diese Todesliganden dar. Jedoch wurde keine Auswirkung von Atorvastatin auf die T-Zellaktivierung beobachtet, da der Einstrom von extrazellulärem Kalzium nicht beeinflußt wurde. Während Studien zum TRAIL-vermittelten Einfluß auf die T-Zell-Aktivierung und dem Zellzyklus erst in der präklinischen Phase sind, werden Statine, die ebenfalls den Zellzyklus beeinflussen, bereits in der Therapie anderer Erkrankungen angewand. Darüber hinaus werden derzeit bereits klinische Studien mit Statinen zur MS-Therapie durchgeführt. Weitere Untersuchungen zu den detaillierten Mechanismen antiproliferativer Substanzen mit potenziellem therapeutischen Effekt in der MS ermöglichen die Entwicklung von selektiveren immunomodulatorischen Therapien mit höherem therapeutischen Nutzen für MS-Patienten. / Multiple sclerosis (MS) is a heterogeneous disease of the central nervous system whose pathological mechanisms are far from completely understood. The current hypothesis is that pro-inflammatory T cells are orchestrating the pathogenesis of this condition. It is considered that a dysregulation in T cell control to be involved, with an imbalance in apoptosis-regulating molecules possibly playing a role. In fact, therapeutic strategies aim to reduce T cell activation, proliferation and cytokine production or to promote T cell elimination. The focus of this thesis was to identify the role of regulatory molecules for T cell survival in the immune pathogenesis of MS, and to investigate antiproliferative or apoptosis-promoting effects on T cells by potential therapeutic molecules. A limitation in the apoptotic regulation of autoreactive T cells in the periphery and in the CNS may contribute to the pathophysiology of MS. As key regulators of apoptosis, members of the Bcl-2 family were investigated in both MS patients and controls. These factors were examined in relation to the susceptibility of T cells, from both groups, towards activation-induced cell death (AICD). To mimic the in vivo elimination of antigen-reactive T cells, an in vitro model of AICD involving repetitive T cell receptor mediated stimulation was utilized. In fact, polyclonal T cells from MS patients showed a decreased susceptibility to undergo AICD as shown by both caspase activity (p=0.013) and DNA fragmentation (p=0.0071) assays. Furthermore, Bcl-XL protein levels, as measured by immunoblotting, were increased in the peripheral immune cells of MS patients (p=0.014). An inverse correlation observed between Bcl-XL levels and susceptibility of T cells to undergo AICD is in line with previous data on the significance of this anti-apoptotic protein in T cell resistance. Since this molecule has already been shown to aggravate the outcome of experimental autoimmune encephalitis, the animal model for MS, the observation of elevated Bcl-XL levels in patients offers perspectives towards therapeutic manipulation in MS. Apart from promoting apoptotic elimination, current therapeutic strategies aim at inhibiting activation and further proliferation of potentially harmful T cells. Based on clinical experience with rather non-selective therapies that promote T cell elimination, a therapeutic goal is to identify newer immunomodulatory substances with better selectivity in order to maximize the therapy's benefit to risk ratio. Thus, two different substances, both interfering with cell cycle regulation, were investigated. The first candidate was the recently discovered member of the TNF/NGF family of death ligands, TNF-related apoptosis inducing ligand (TRAIL) since it has been reported to have immunoregulatory functions and since human antigen-specific T cells were shown to be resistant towards apoptosis induction by this ligand. The second candidate drug with potential in MS therapy is atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme (HMG-CoA) reductase inhibitor and lipid-lowering drug, already indicated for anomalies in lipid metabolism. In order to prove the hypothesis that these substances interfere with T cell receptor signaling, human antigen-specific T cell lines from both MS patients and controls, characterized with regards to T helper differentiation and peptide specificity, were employed. Exogenous treatment of TRAIL resulted in an inhibition in proliferation, albeit to varying degrees (6.2% - 63.8% inhibition). Atorvastatin also inhibited proliferation of antigen-specific T cell lines in a dose-dependent manner. Both compounds induced hypoproliferation independently of antigen presentation, as shown by their ability to block T cell proliferation in response to direct T cell receptor engagement, thus indicating a direct influence on T cell function. The growth inhibition by TRAIL was associated with a downregulation of the cell cycle regulator CDK4, indicative of an inhibition of cell cycle progression at the G1/S transition. Incubating T cells with atorvastatin also induced a downregulation of CDK4 expression, which was accompanied by an upregulation of p27Kip1 expression. The atorvastatin-mediated inhibition in proliferation and cell cycle progression could be reversed by mevalonate, an intermediate product of the HMG-CoA reductase pathway, suggesting a direct involvement of atorvastatin in this pathway, necessary for the isoprenylation of small GTPase proteins of the Rho family. Utilizing a thapsigargin model of calcium influx to activate the same calcium-release activated calcium (CRAC) channels as T cell receptor-stimulation by antigen, an inhibition in calcium influx could be observed on pre-incubating T cells with TRAIL. Co-incubating with human recombinant TRAIL receptor 2 fusion protein, a competitive antagonist for TRAIL, reversed this inhibition. A direct influence on calcium influx is indicative of an influence of TRAIL on the activation status of human T cells. Therefore, TRAIL directly inhibits activation of these cells via blockade of calcium influx. However, no impact of atorvastatin on early T cell activation was observed, since calcium influx was unaffected. While TRAIL-mediated interference with T cell activation and further cell cycle progression is still in the pre-clinical phase, statins, which have also been shown here to interfere with the T cell cycle, are already employed in the clinic for other ailments. In fact, clinical trials are currently being undertaken with this group of drugs for MS. Further studies on detailed mechanisms of antiproliferative substances effective in MS will allow the development of highly selective immunomodulatory agents with increased beneficial profile as MS therapy.

Text in Afrikaans / In this study Gestalttechniques within a group work-program as intervention was used to bring awaiting-trail youth in detention in contact with themselves and to broaden their awareness. The goal of the research is to determine if the Gestalt groupworkprogram have a influence on the self-image and general satisfaction of the awaiting-trail adolescent. To reach the above goal the researcher used applied research. Standardised measure-instruments as well as observation was used. Gestaltgroupwork can be implemented with great success in residential institutions like secure care facilities for children. / In hierdie studie is Gestalttegnieke binne 'n groepwerkprogram benut as intervensie, om die verhoorafwagtende jeugdige in aanhouding weer in kontak te bring met homself en om sy bewustheidskontinuum te vergroot. Die doel van die navorsing was om te bepaal of die Gestaltgroepwerkprogram 'n invloed sal he op die selfbeeld en algemene tevredenheid van die verhoorafwagtende adolessent. Om bogenoemde te bereik het die navorser toegepaste navorsing onderneem en het van sowel waarneming as gestandaardiseerde meetinstrumente gebruik gemaak. Die teoretiese onderbou van die behandelingsprogram wat gebruik is spruit uit die Gestaltterapie en kan met groot sukses geimplementeer word in residensiele inrigtings soos bewaarsorgsentrums vir kinders. / Social Work / M.Diac. (Spelterapie)

La leucémie aigüe lymphoblastique de précurseurs des cellules B (pré-B LAL) est le cancer le plus fréquent chez l’enfant. La transplantation de cellules souches hématopoïétiques (TCSH) est nécessaire dans environ 20 à 30 % des enfants ayant une pré-B LAL. Les rechutes après TCSH sont habituellement réfractaires aux thérapies actuelles, et par conséquent, il est important de développer et d’optimiser de nouvelles stratégies thérapeutiques. Dans cette étude, nous nous sommes intéressés aux cellules « cytokine-induced killer » (CIK). En effet, ces cellules ont été montrées comme hautement cytotoxique contre beaucoup de types de cancers. Cependant, leur activité cytotoxique contre les pré-B LAL n’est pas vraiment efficace. Par conséquent, nous avons étudié la possibilité de combiner l’immunothérapie des cellules CIK avec l’interféron alpha (IFN-α) afin d’optimiser l’activité lytique de ces cellules contre les cellules pré-B LAL. De plus, vu qu’il a été démontré que l’activité cytotoxique des cellules CIK provient de la fraction CD56+, plus particulièrement les cellules CD3+CD56+, nous avons décidé d’utiliser la fraction CD56+ (cellules CD56+) dans l’ensemble de nos expériences. Nous avons observé in vitro que les cellules CD56+ lysent mieux les lignées cellulaires pré-B LAL comparativement aux cellules CIK non purifiées. Aussi, leur activité cytotoxique peut être augmentée par le traitement avec l’IFN-α. Par ailleurs, nous avons démontré l’efficacité des cellules CD56+ traitées par l’IFN-α contre les lignées cellulaires pré- B LAL in vivo, dans le modèle de souris NOD/SCID/gamma c- (NSG). La survie des souris est significativement prolongée lorsqu’elles reçoivent les cellules pré-B LAL avec les cellules CD56+ traitées par l’IFN-α. Nous avons par la suite étudié le mécanisme d’action des cellules CD56+ contre les lignées cellulaires pré-B LAL. Nous avons observé que les cellules CD56+ provenant de sang de cordon sont plus efficaces que les cellules CD56+ provenant de sang I périphérique pour tuer les lignées cellulaires pré-B LAL. Nous avons également montré que les cellules CD56+ utilisent seulement la voie NKG2D ou bien les voies NKG2D et TRAIL selon la lignée cellulaire pré-B LAL cible et selon la provenance de la source des cellules CD56+. Par ailleurs, nous avons remarqué que les cellules CIK sont sensibles à l’apoptose par Fas, et que cette sensibilité influence leur activité cytotoxique contre les cellules tumorales. En conclusion, les cellules CD56+ sont cytotoxiques contre les lignées cellulaires pré-B LAL, et leur effet lytique est augmenté par l’IFN-α aussi bien in vitro qu’in vivo dans le modèle de souris NSG. Ces données précliniques sont encourageantes pour tester cette nouvelle approche d’immunothérapie dans le traitement contre la pré-B LAL. / Precursor B-cell acute lymphoblastic leukemia (B-ALL) is the most common form of leukemia in children. Hematopoietic stem cell transplantation (HSCT) is required in around 20 to 30% of children with a B-ALL. The relapses occuring post-HSCT are usually insensitive to current therapy. Therefore, it is important to develop and optimize a new therapeutic strategy. In this study, we were interested to study « cytokine-induced killer » (CIK) cells. These cells have been shown to be very cytotoxic against many types of tumor. However, their cytotoxic activity against B-ALL cells is not very efficient. Consequently, we have studied the effect of combining adoptive immunotherapy of CIK cells with the interferon alpha (IFN-α) to increase their lytic activity against B-ALL cells. In addition, in the literature, the cytotoxic activity of CIK cells has been shown to come from the CD56+ fraction (CD56+ CIK), in particular CD3+CD56+ cells. Therefore, we used the CD56+ fraction in all the experiments. We have observed in vitro that CD56+ CIK cells killed more efficiently B-ALL cell lines than did non-purified CIK cells. Also, their cytotoxic activity could be enhanced with IFN-α. Moreover, we have demonstrated the efficacy of IFN-α-treated-CD56+ CIK cells against B-ALL cell lines in vivo in the model of NOD/SCID/gamma c- (NSG) mice by showing that the survival of mice injected with B-ALL cell lines was significantly increased when they were injected with IFN-α-treated-CD56+ CIK cells. Subsequently, we have studied the lytic mechanism of CD56+ CIK cells against B-ALL cell lines. We have observed that CD56+ CIK cells from cord blood were more efficient than CD56+ CIK cells from peripheral blood to kill B-ALL cell lines. CD56+ CIK cells used only the NKG2D pathway or the both NKG2D and TRAIL pathways depending on the B-ALL cell line and the source of CIK cells. In addition, we showed that CIK cells were sensitive to Fas apoptosis. This sensitivity III influenced the cytotoxic activity of CIK cells against tumor cells. In conclusion, CD56+ CIK cells are cytotoxic against B-ALL cell lines, and their effect can be increased with IFN-α in vitro and in vivo. Taken together, our pre-clinical data are very interesting for testing the potential clinical utility of purified CD56+ CIK cells as an immunotherapeutic strategy for B- ALL patients.

Introdução: Este estudo foi realizado com o intuito de avaliar efeitos da acupuntura sobre os pacientes com asma leve e moderada persistentes com o uso de beta-2 agonista ou corticoide inalatório. Métodos e casuística: Trata-se de um estudo prospectivo, duplo-cego, randomizado e cruzado com dois braços. Os 74 pacientes com diagnóstico de asma leve/moderada, de acordo com a classificação de GINA 2002/2003, foram divididos em dois grupos, sendo 31 do Grupo I, e 43 do Grupo II inicialmente. Foram realizadas consultas médicas e exames que incluíram espirometria, citologia de escarro induzido, NO expirado, preenchimento de escala de sintoma, questionários de qualidade de vida de asma e de SF 36, e realização de peak-flow, dependendo da Fase do protocolo. A Fase I constituiu-se dos exames pré-intervenção. Na Fase II, foram realizadas 10 sessões de Acupuntura Real no Grupo I e 10 sessões de Acupuntura Sham no Grupo II, na Fase III, houve 4 semana de washout, na Fase IV, houve a troca de técnicas de acupuntura, sendo uma sessão por semana e, na Fase V, realização dos exames. Resultados: Não há diferença nos critérios de avaliação no pré-tratamento entre dois grupos, com exceção de maior celularidade inflamatória no Grupo II. No entanto, houve uma redução significativa de eosinófilos (p = 0,035) e neutrófilos (p = 0,047), e aumento de macrófagos (p = 0,001), melhora da medida de volume do peak-flow (p = 0,01) na fase IV do Grupo II. No Grupo I, na avaliação de escala de sintomas diária, havia menor uso de medicação de resgate (p = 0,043) na Fase II, e, depois de receber a Acupuntura Sham na Fase IV, havia menos tosse (p = 0,007), menos chiado (p = 0,037), menos dispneia (p < 0,001) e menor uso de medicação de resgate (p < 0,001). No Grupo II, após receber o tratamento com a Acupuntura Sham na Fase II, houve diminuição de tosse (p = 0,037), de chiado (p = 0,013) e de dispneia (p = 0,014), e, na Fase IV, havia menos tosse (p = 0,040), sibilos (p = 0,012), dispneia (p < 0,001) e menos despertares noturnos (p = 0,009). Nos questionários de qualidade de vida de asma e de SF 36, foram encontrados alguns aspectos de melhora significantes na Acupuntura Sham dos dois grupos em relação à Fase I, mas os resultados da Acupuntura Real tiveram maiores índices de melhora em relação aos resultados da Acupuntura Sham nos dois grupos. Mas não há diferença significativa entre os dois na qualidade de vida de SF 36. Entretanto, não houve alteração de avaliação de espirometria e de óxido nítrico expirado. Conclusão: Este estudo demonstrou que o uso de Acupuntura Real num grupo de pacientes com a celularidade mais inflamatória teve melhor resultados de sintomas diários, tais como dispneia e despertar noturno, de medida de volume de peak-flow matutina, e de avaliação de qualidade de vida em asma e SF36, além da diminuição quantitativa de neutrófilos e de eosinófilos, com aumento de macrófagos, que justificam os efeitos anti-inflamatórios e imunitários. A acupuntura é uma terapia segura, não havendo nenhum efeito colateral observado neste projeto que possa interferir com a vida cotidiana e pode ser de grande auxílio no alívio de sintomas, com melhora de qualidade de vida e, possivelmente, pode ter uma ação na modulação do processo inflamatório de vias aéreas / Introduction: This survey has been conducted in order to evaluate the effects of acupuncture in patients with persistent mild and moderate asthma (according to GINA criteria 2003), using beta agonist and/or inhaled glucocorticoid. Methods and patients: This is a prospective, double blinded, randomized and cross-over study with two branches: 74 patients diagnosed with mild and moderate asthma were divided into two groups: Group I with 31, initiating with real acupuncture and Group II, starting with sham acupuncture. Medical interview and laboratory tests including spirometry, induced sputum citology, exhaled NO measurement, quality of life questionnaire (SF-36 and QQL), besides, daily symptom scores and measurement of peak-flow were performed, in the beginning of the study, and in the end of each phase of treatment. Phase I: laboratory tests and other qualitative measurements. There were 10 real acupuncture weekly sessions to Group I and 10 sham acupuncture sessions to Group II in Phase II. On the other hand, in the Phase IV, there was an exchange between Group I and Group II, which was receiving real acupuncture started to receive sham, and vice-versa, the number of sessions remained the same (10 weekly sessions). Phase III, during the interval between Phase II and Phase IV, there was an interval of 4 weeks of washout. Phase V: laboratory tests and other qualitative measurements. Results: There was no difference beween both the groups in all criteria of evaluation pré treatment, with only na exception: in the Group II there was large inflammatory cell counts. However, there was a significant reduction in eosinophils (p = 0.035) and neutrophils (p = 0.047), and increase of macrophages (p = 0.001), improved peak-flow measurement in the morning (p = 0.01) in Group II (started with sham) in Phase IV. In Daily Symptons Score, there was a significant reduction in use of rescue medication (p = 0.043) in Group I (real acupuncture) in Phase II and after received sham acupuncture (Phase IV), there were less cough (p = 0.007), less wheezing (p = 0.037), less dyspnea (p < 0.001) e less use of rescue medication (p < 0.001). In Group II, after received sham (Phase II), there were less cough (p = 0.037), less wheezing (p = 0.013) and less dyspnea (p = 0.014). In Phase IV, less cough (p = 0.040), wheezing (p = 0.012), dyspnea (p < 0.001) and less nocturnal awakening (p = 0.009). In the questionnaires of quality of life SF-36 and QQL, several domains were found to be improved after received sham acupuncture in both groups, comparing phase II against phase I, but the results found after received real acupuncture were better than sham in both groups. Although there was no statistic difference between both groups. However, there was no difference in exhaled NO and spirometry measurement. Conclusion: This survey demonstrated that the use of real acupuncture in a group of patients with large inflammatory cells counts could have contributed to reduce symptoms, improve quality of life, improved peak-flow measurement in the morning and reduced inflammatory cells count in induced sputum, therefore, acupuncture is a safe healing techniques, presented no adverse effects observed in this study, and could of great help in treatment of patients with mild and moderate asthma

Outdoor recreation and heritage resources have the potential to provide a wide range of benefits to individuals, groups of individuals and the economy. An increased knowledge of these benefits can give recreation managers and planners a better understanding of how their actions and decisions regarding a resource may impact upon the visitors and communities that they serve. Placed within a climate of increasing public sector accountability, this information might also prove useful in justifying the allocation of scarce resources to recreation and heritage preservation. Justifying the value that recreation adds to society is an issue recognised by Benefits Based Management (BBM), a recreation management and planning framework that seeks to identify and target the positive outcomes realised by individuals, groups, local businesses and communities that result from participation in recreation and leisure. To date, recreation planners and managers have not been presented with a BBM research effort that seeks to describe and understand the visitor and community benefits associated with a rail to trail conversion. This study aimed to identify and describe benefits gained by visitors and neighbouring communities, with specific reference to the Otago Central Rail Trail (OCRT), Central Otago, New Zealand. Information was gathered from seventy-seven semi-structured interviews with visiting users of the OCRT, residents of neighbouring communities and trail managers. The results of the study indicated that community stakeholders reported benefits such as local economic development linked to visitor expenditure, heightened sense of community identity and solidarity and social contact with people from outside the local area. An additional finding was that the perceived benefits of the OCRT have reportedly had a positive influence on local people's attitudes towards the rail trail. Visitor interviews revealed that personal and social well-being benefits such as physical activity, aesthetic appreciation, sense of achievement, psychological refreshment, family togetherness and social interaction with friends and local people were outcomes of an OCRT visit. Reported visitor benefits were further linked to physical fitness and health, enhanced mood and positive mental state, leading a balanced lifestyle and stronger relationships within families and between friends. Visitors also perceived that an OCRT visit had forged a greater knowledge and awareness of railway heritage through gaining insight into railway and Central Otago history and appreciation of the engineering skills and craftsmanship associated with 19th century railway construction. Following the benefit chain of causality (Driver, 1994; Driver & Bruns, 1999; McIntosh, 1999), interview responses were linked to potential community and visitor benefits that could be realised off-site such as enhanced quality of life, community satisfaction and a greater connection with and appreciation of New Zealand's historic and cultural heritage.